FIELD: biotechnology.
SUBSTANCE: human epidermal growth factor 2 (HER2) receptor antibody is proposed, as well as pharmaceutical compositions comprising the said antibody for malignant tumour prevention and treatment and for apoptosis induction. In addition, a kit for malignant tumour diagnosing, comprising the said antibody, is provided.
EFFECT: invention allows cancer cells destruction with significantly increased cytotoxicity when used in combination with trastuzumab and can be used for cancer therapy.
11 cl, 27 dwg, 10 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTI-HER2 ANTIBODY AND CONJUGATE THEREOF | 2014 |
|
RU2656161C1 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
| BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3 | 2020 |
|
RU2827106C1 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTI-CLAUDIN 18.2 ANTIBODY AND ITS ANTIBODY-DRUG CONJUGATE | 2022 |
|
RU2814164C2 |
| NOVEL ANTI-CLDN18.2 ANTIBODIES | 2020 |
|
RU2830887C2 |
| ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
| DOUBLE SPECIFICITY ANTIBODIES | 2014 |
|
RU2732032C2 |
| ANTIBODY-DRUG CONJUGATES BASED ON ERIBULIN AND APPLICATION METHODS | 2017 |
|
RU2754369C2 |
